Literature DB >> 22017478

Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature.

Bruno Bockorny1, Ion Codreanu, Constantin A Dasanu.   

Abstract

Richter transformation in chronic lymphocytic leukaemia (CLL) represents an entity of considerable genetic, molecular, immunological and clinical heterogeneity. A rare occurrence, Hodgkin variant of Richter syndrome, has not been comprehensively characterized or systematized to date. We conducted a retrospective analysis of the existing cases of Hodgkin lymphoma as Richter syndrome reported in the medical literature in the previous three and a half decades. Our search identified 86 such patients; this entity affects predominantly older men and the most common histological subtype is mixed cellularity. Interval between the diagnosis of CLL and subsequent development of Hodgkin lymphoma is circa 4.3 years. The overall survival of patients was approximately 1.7 years in our analysed cohort. However, our pooled data showed that patients in whom CLL had been treated with fludarabine had a shorter survival after transformation compared to the ones not treated with this agent. The role of immunosuppression and Epstein-Barr virus infection in the aetiopathogenesis of this entity remains to be clarified.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22017478     DOI: 10.1111/j.1365-2141.2011.08907.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  31 in total

Review 1.  Richter transformation in the era of novel agents.

Authors:  Wei Ding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Hodgkin's lymphoma as Richter's transformation in chronic lymphocytic leukemia.

Authors:  Alberto Fabbri; Emanuele Cencini; Monica Bocchia
Journal:  Med Oncol       Date:  2014-03-07       Impact factor: 3.064

3.  How we treat Richter syndrome.

Authors:  Sameer A Parikh; Neil E Kay; Tait D Shanafelt
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

4.  Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.

Authors:  Sameer A Parikh; Thomas M Habermann; Kari G Chaffee; Timothy G Call; Wei Ding; Jose F Leis; William R Macon; Susan M Schwager; Kay M Ristow; Luis F Porrata; Neil E Kay; Susan L Slager; Tait D Shanafelt
Journal:  Am J Hematol       Date:  2015-01-30       Impact factor: 10.047

Review 5.  Chronic lymphocytic leukaemia.

Authors:  Thomas J Kipps; Freda K Stevenson; Catherine J Wu; Carlo M Croce; Graham Packham; William G Wierda; Susan O'Brien; John Gribben; Kanti Rai
Journal:  Nat Rev Dis Primers       Date:  2017-01-19       Impact factor: 52.329

6.  Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.

Authors:  Alankrita Taneja; Jade Jones; Stefania Pittaluga; Irina Maric; Mohammed Farooqui; Inhye E Ahn; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-07-06

7.  Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion.

Authors:  Wenbin Xiao; Wayne W Chen; Lynn Sorbara; Theresa Davies-Hill; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Hum Pathol       Date:  2016-05-14       Impact factor: 3.466

Review 8.  Treatment of Richter's Syndrome.

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Curr Treat Options Oncol       Date:  2017-11-21

9.  Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.

Authors:  O Al-Sawaf; S Robrecht; J Bahlo; A M Fink; P Cramer; J V Tresckow; E Lange; M Kiehl; M Dreyling; M Ritgen; J Dürig; E Tausch; C Schneider; S Stilgenbauer; C M Wendtner; K Fischer; M Hallek; B Eichhorst
Journal:  Leukemia       Date:  2020-03-17       Impact factor: 11.528

10.  Richter Syndrome in Chronic Lymphocytic Leukemia.

Authors:  Candida Vitale; Alessandra Ferrajoli
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.